Claimed effect · Vilon

Does Vilon help with any outcome in humans?

D
Grade D — no human evidence0 · effect size: not measurable
Short answerNo human evidence. As of 23 September 2026, only 0 exists for Vilon for any outcome in humans. A PubMed search returns 57 results, none a human trial. The 'chromatin reactivation' work used lymphocytes from elderly donors in culture.

What the studies show

A PubMed search returns 57 results, none a human trial. The 'chromatin reactivation' work used lymphocytes from elderly donors in culture.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

  1. 1

In context

Vilon is the dipeptide lysine–glutamate, one of the short synthetic peptides derived by Vladimir Khavinson's St Petersburg institute from thymic extracts and sold as an immune and anti-ageing 'bioregulator'. Its indexed evidence is mice — longer lifespan and fewer spontaneous tumours in the institute's own studies — and cultured cells. No human trial of any design exists. It is not approved anywhere this site covers.

Vilon is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Vilon proven to help with any outcome in humans?
No. There is no human evidence for it (0); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
A PubMed search returns 57 results, none a human trial. The 'chromatin reactivation' work used lymphocytes from elderly donors in culture.
Is Vilon approved for this?
No. Vilon is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Vilon

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →